Urogen Pharma (URGN) Given Average Rating of “Strong Buy” by Analysts
Urogen Pharma (NASDAQ:URGN) has received an average broker rating score of 1.25 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and three have assigned a strong buy rating to the company.
Brokerages have set a 1 year consensus target price of $28.00 for the company and are anticipating that the company will post ($0.05) EPS for the current quarter, according to Zacks. Zacks has also given Urogen Pharma an industry rank of 104 out of 265 based on the ratings given to its competitors.
URGN has been the topic of several research reports. Zacks Investment Research raised Urogen Pharma from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Wednesday, August 2nd. Oppenheimer Holdings, Inc. set a $32.00 target price on Urogen Pharma and gave the stock a “buy” rating in a research report on Monday, August 14th. Cowen and Company initiated coverage on Urogen Pharma in a research report on Tuesday, May 30th. They issued an “outperform” rating on the stock. Jefferies Group LLC initiated coverage on Urogen Pharma in a research report on Tuesday, May 30th. They issued a “buy” rating and a $27.00 target price on the stock. Finally, Raymond James Financial, Inc. initiated coverage on Urogen Pharma in a research report on Tuesday, May 30th. They issued an “outperform” rating and a $25.00 target price on the stock.
COPYRIGHT VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/08/urogen-pharma-urgn-given-average-rating-of-strong-buy-by-analysts.html.
Urogen Pharma (URGN) opened at 28.48 on Friday. The stock has a 50 day moving average price of $19.36 and a 200 day moving average price of $18.14. Urogen Pharma has a 1-year low of $13.01 and a 1-year high of $29.89. The firm’s market capitalization is $370.50 million.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Alps Advisors Inc. bought a new stake in shares of Urogen Pharma during the 2nd quarter worth about $195,000. LLBH Private Wealth Management LLC bought a new stake in shares of Urogen Pharma during the 2nd quarter worth about $695,000. Spark Investment Management LLC bought a new stake in shares of Urogen Pharma during the 2nd quarter worth about $856,000. Menora Mivtachim Holdings LTD. bought a new stake in shares of Urogen Pharma during the 2nd quarter worth about $2,331,000. Finally, Wildcat Capital Management LLC bought a new stake in shares of Urogen Pharma during the 2nd quarter worth about $2,439,000. Institutional investors own 36.06% of the company’s stock.
Urogen Pharma Company Profile
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.